|
SE370449B
(enExample)
|
1970-08-29 |
1974-10-14 |
Philips Nv |
|
|
JPS5334319B2
(enExample)
|
1971-12-28 |
1978-09-20 |
|
|
|
JPS5717624B2
(enExample)
|
1974-04-17 |
1982-04-12 |
|
|
|
JPS59878B2
(ja)
|
1975-09-04 |
1984-01-09 |
松下電工株式会社 |
感知器
|
|
US4208479A
(en)
|
1977-07-14 |
1980-06-17 |
Syva Company |
Label modified immunoassays
|
|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
JPS58201994A
(ja)
|
1982-05-21 |
1983-11-25 |
Hideaki Hagiwara |
抗原特異的ヒト免疫グロブリンの生産方法
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
JPH0234615Y2
(enExample)
|
1986-08-08 |
1990-09-18 |
|
|
|
JPH06104071B2
(ja)
|
1986-08-24 |
1994-12-21 |
財団法人化学及血清療法研究所 |
第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
|
|
US6121424A
(en)
|
1991-11-25 |
2000-09-19 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
US5670373A
(en)
*
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
|
US6010902A
(en)
|
1988-04-04 |
2000-01-04 |
Bristol-Meyers Squibb Company |
Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
|
|
US5126250A
(en)
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
|
IL89491A0
(en)
|
1988-11-17 |
1989-09-10 |
Hybritech Inc |
Bifunctional chimeric antibodies
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
JPH0341033A
(ja)
|
1989-07-07 |
1991-02-21 |
Kyowa Hakko Kogyo Co Ltd |
安定なモチリン類含有製剤
|
|
GB8916400D0
(en)
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
|
AU649952B2
(en)
|
1989-12-11 |
1994-06-09 |
Immunomedics Inc. |
Method for antibody targeting of diagnostic or therapeutic agents
|
|
US5859205A
(en)
*
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
TW212184B
(enExample)
|
1990-04-02 |
1993-09-01 |
Takeda Pharm Industry Co Ltd |
|
|
JPH05184383A
(ja)
|
1990-06-19 |
1993-07-27 |
Dainabotsuto Kk |
二重特異性抗体
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
JPH06508511A
(ja)
|
1990-07-10 |
1994-09-29 |
ケンブリッジ アンティボディー テクノロジー リミティド |
特異的な結合ペアーの構成員の製造方法
|
|
JPH05199894A
(ja)
|
1990-08-20 |
1993-08-10 |
Takeda Chem Ind Ltd |
二重特異性抗体および抗体含有薬剤
|
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
|
ES2134212T3
(es)
*
|
1991-04-25 |
1999-10-01 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
|
|
JPH05304992A
(ja)
|
1991-06-20 |
1993-11-19 |
Takeda Chem Ind Ltd |
ハイブリッド・モノクローナル抗体および抗体含有薬剤
|
|
US5637481A
(en)
*
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
|
ATE181571T1
(de)
|
1991-09-23 |
1999-07-15 |
Medical Res Council |
Methoden zur herstellung humanisierter antikörper
|
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
|
ATE463573T1
(de)
|
1991-12-02 |
2010-04-15 |
Medimmune Ltd |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
|
EP0746609A4
(en)
|
1991-12-17 |
1997-12-17 |
Genpharm Int |
NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
|
|
US5667988A
(en)
|
1992-01-27 |
1997-09-16 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
|
JPH05203652A
(ja)
|
1992-01-28 |
1993-08-10 |
Fuji Photo Film Co Ltd |
抗体酵素免疫分析法
|
|
JPH05213775A
(ja)
|
1992-02-05 |
1993-08-24 |
Otsuka Pharmaceut Co Ltd |
Ｂｆａ抗体
|
|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
|
EP0656941B1
(en)
|
1992-03-24 |
2005-06-01 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US6129914A
(en)
*
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
|
US5744446A
(en)
|
1992-04-07 |
1998-04-28 |
Emory University |
Hybrid human/animal factor VIII
|
|
JPH07509137A
(ja)
|
1992-07-24 |
1995-10-12 |
セル ジェネシス，インク． |
異種抗体の生産
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
ZA936260B
(en)
|
1992-09-09 |
1994-03-18 |
Smithkline Beecham Corp |
Novel antibodies for conferring passive immunity against infection by a pathogen in man
|
|
US5837821A
(en)
*
|
1992-11-04 |
1998-11-17 |
City Of Hope |
Antibody construct
|
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
|
SG55079A1
(en)
*
|
1992-12-11 |
1998-12-21 |
Dow Chemical Co |
Multivalent single chain antibodies
|
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
|
WO1995001571A1
(en)
|
1993-07-01 |
1995-01-12 |
Baxter Diagnostics Inc. |
Process for the preparation of factor x depleted plasma
|
|
UA40577C2
(uk)
|
1993-08-02 |
2001-08-15 |
Мерк Патент Гмбх |
Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
|
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
|
CA2177988A1
(en)
|
1993-12-03 |
1995-06-08 |
Kazuo Higuchi |
Expression vector for preparing an anti-body-variable-region library
|
|
EP0731842A1
(en)
|
1993-12-03 |
1996-09-18 |
Medical Research Council |
Recombinant binding proteins and peptides
|
|
DE122009000068I2
(de)
*
|
1994-06-03 |
2011-06-16 |
Ascenion Gmbh |
Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
|
|
US5945311A
(en)
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
|
US8017121B2
(en)
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
|
CA2194369C
(en)
|
1994-07-11 |
2004-08-31 |
Philip E. Thorpe |
Methods and compositions for the specific coagulation of vasculature
|
|
KR100261941B1
(ko)
|
1994-07-13 |
2000-07-15 |
나가야마 오사무 |
사람의 인터루킨-8에 대한 재구성 사람항체
|
|
CA2195557C
(en)
|
1994-08-12 |
2006-10-17 |
Shui-On Leung |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
|
US6451523B1
(en)
*
|
1994-09-14 |
2002-09-17 |
Interneuron Pharmaceuticals, Inc. |
Detection of a leptin receptor variant and methods for regulating obesity
|
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
|
EP0783893B1
(en)
|
1994-10-07 |
2012-04-04 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
|
|
WO1996012503A1
(en)
|
1994-10-21 |
1996-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
Remedy for diseases caused by il-6 production
|
|
WO1996016673A1
(en)
|
1994-12-02 |
1996-06-06 |
Chiron Corporation |
Method of promoting an immune response with a bispecific antibody
|
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
|
WO1996026648A1
(en)
|
1995-02-28 |
1996-09-06 |
The Procter & Gamble Company |
Preparation of noncarbonated beverage products having superior microbial stability
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
EP0822830B1
(en)
|
1995-04-27 |
2008-04-02 |
Amgen Fremont Inc. |
Human anti-IL-8 antibodies, derived from immunized xenomice
|
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69636015T2
(de)
|
1995-05-03 |
2007-01-04 |
Bioenhancementsments Ltd. |
Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
|
|
WO1997010354A1
(fr)
|
1995-09-11 |
1997-03-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
|
|
DE69734443T2
(de)
|
1996-01-08 |
2006-07-13 |
Genentech, Inc., South San Francisco |
Ob-rezeptor und liganden
|
|
MA24512A1
(fr)
|
1996-01-17 |
1998-12-31 |
Univ Vermont And State Agrienl |
Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
|
|
FR2745008A1
(fr)
|
1996-02-20 |
1997-08-22 |
Ass Pour Le Dev De La Rech En |
Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre
|
|
US5945231A
(en)
*
|
1996-03-26 |
1999-08-31 |
California Institute Of Technology |
Direct liquid-feed fuel cell with membrane electrolyte and manufacturing thereof
|
|
JP3032287U
(ja)
|
1996-06-10 |
1996-12-17 |
幸喜 高橋 |
人 形
|
|
US20020147326A1
(en)
|
1996-06-14 |
2002-10-10 |
Smithkline Beecham Corporation |
Hexameric fusion proteins and uses therefor
|
|
AU720232B2
(en)
|
1996-07-19 |
2000-05-25 |
Amgen, Inc. |
Analogs of cationic proteins
|
|
SK40599A3
(en)
|
1996-09-26 |
2000-06-12 |
Chugai Pharmaceutical Co Ltd |
Antibody against human parathormone related peptides
|
|
JPH10165184A
(ja)
|
1996-12-16 |
1998-06-23 |
Tosoh Corp |
抗体、遺伝子及びキメラ抗体の製法
|
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
|
US6323000B2
(en)
|
1996-12-20 |
2001-11-27 |
Clark A. Briggs |
Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
|
|
ATE383430T1
(de)
|
1997-03-20 |
2008-01-15 |
Us Gov Health & Human Serv |
Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
|
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
US20070059302A1
(en)
*
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
FR2761994B1
(fr)
|
1997-04-11 |
1999-06-18 |
Centre Nat Rech Scient |
Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
|
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
DE19725586C2
(de)
|
1997-06-17 |
1999-06-24 |
Gsf Forschungszentrum Umwelt |
Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
|
|
US6368596B1
(en)
*
|
1997-07-08 |
2002-04-09 |
Board Of Regents, The University Of Texas System |
Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
|
US5980893A
(en)
|
1997-07-17 |
1999-11-09 |
Beth Israel Deaconess Medical Center, Inc. |
Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
|
|
US6207805B1
(en)
|
1997-07-18 |
2001-03-27 |
University Of Iowa Research Foundation |
Prostate cell surface antigen-specific antibodies
|
|
US20020187150A1
(en)
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
|
US6342220B1
(en)
*
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
AU750453B2
(en)
*
|
1997-10-03 |
2002-07-18 |
Chugai Seiyaku Kabushiki Kaisha |
Natural human antibody
|
|
HU225539B1
(en)
|
1998-03-17 |
2007-02-28 |
Chugai Pharmaceutical Co Ltd |
Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor
|
|
AU752730B2
(en)
|
1998-04-03 |
2002-09-26 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
|
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US7081360B2
(en)
*
|
1998-07-28 |
2006-07-25 |
Cadus Technologies, Inc. |
Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
|
|
US20020142374A1
(en)
*
|
1998-08-17 |
2002-10-03 |
Michael Gallo |
Generation of modified molecules with increased serum half-lives
|
|
WO2000018806A1
(de)
|
1998-09-25 |
2000-04-06 |
Horst Lindhofer |
Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
|
|
CA2352572C
(en)
|
1998-12-01 |
2010-04-20 |
Abbvie Biotherapeutics Inc. |
Humanized antibodies to gamma-interferon
|
|
US7286585B2
(en)
*
|
1998-12-21 |
2007-10-23 |
Finisar Corporation |
Low temperature grown layers with migration enhanced epitaxy adjacent to an InGaAsN(Sb) based active region
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
|
AR030019A1
(es)
|
1999-05-18 |
2003-08-13 |
Smithkline Beecham Corp |
Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
|
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
AT411997B
(de)
|
1999-09-14 |
2004-08-26 |
Baxter Ag |
Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
|
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
|
US20020028178A1
(en)
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
|
CA2391925A1
(en)
|
1999-11-18 |
2001-05-25 |
Oxford Biomedica (Uk) Limited |
Antibodies
|
|
CA2390662A1
(en)
|
1999-12-14 |
2001-06-21 |
The Burnham Institute |
Bcl-g polypeptides, encoding nucleic acids and methods of use
|
|
AU2001256174A1
(en)
|
2000-03-01 |
2001-09-12 |
Christoph Gasche |
Mammalian interleukin-10 (il-10) receptor variants
|
|
TWI241345B
(en)
|
2000-03-10 |
2005-10-11 |
Chugai Pharmaceutical Co Ltd |
Apoptosis inducing polypeptide
|
|
WO2001070775A2
(en)
|
2000-03-22 |
2001-09-27 |
Curagen Corporation |
Wnt-1 related polypeptides, and nucleic acids encoding the same
|
|
KR20020091170A
(ko)
|
2000-03-31 |
2002-12-05 |
아이덱 파마슈티칼즈 코포레이션 |
Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
|
|
EP1325338A2
(en)
*
|
2000-04-03 |
2003-07-09 |
Oxford GlycoSciences (UK) Limited |
Diagnosis and treatment of alzheimer's disease
|
|
WO2001079494A1
(fr)
|
2000-04-17 |
2001-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps agonistes
|
|
PL366025A1
(en)
|
2000-05-03 |
2005-01-24 |
Munich Biotech Ag |
Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
|
|
JP2004511430A
(ja)
|
2000-05-24 |
2004-04-15 |
イムクローン システムズ インコーポレイティド |
二重特異性免疫グロブリン様抗原結合蛋白および製造方法
|
|
EP1299128A2
(en)
|
2000-06-20 |
2003-04-09 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
AU6461201A
(en)
|
2000-07-12 |
2002-01-21 |
Idec Pharma Corp |
Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
|
|
US7732133B2
(en)
|
2000-07-17 |
2010-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Screening methods for biologically active ligands
|
|
US20020058029A1
(en)
|
2000-09-18 |
2002-05-16 |
Nabil Hanna |
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
|
|
PT1324776E
(pt)
|
2000-10-12 |
2009-12-23 |
Genentech Inc |
Formulações de proteína concentradas de viscosidade reduzida
|
|
US20040242847A1
(en)
*
|
2000-10-20 |
2004-12-02 |
Naoshi Fukushima |
Degraded agonist antibody
|
|
WO2002033072A1
(fr)
|
2000-10-20 |
2002-04-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps degrade, agoniste de tpo
|
|
US8034903B2
(en)
*
|
2000-10-20 |
2011-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Degraded TPO agonist antibody
|
|
EP1327681A4
(en)
|
2000-10-20 |
2004-09-01 |
Chugai Pharmaceutical Co Ltd |
Degraded agonist antibodies
|
|
JP4889187B2
(ja)
|
2000-10-27 |
2012-03-07 |
中外製薬株式会社 |
Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
KR100900176B1
(ko)
|
2001-03-07 |
2009-06-02 |
메르크 파텐트 게엠베하 |
하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
|
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
|
AU2002307062A1
(en)
|
2001-04-02 |
2002-10-15 |
Purdue Pharma L.P. |
Thrombopoietin (tpo) synthebody for stimulation of platelet production
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
MXPA03009390A
(es)
*
|
2001-04-13 |
2004-01-29 |
Biogen Inc |
Anticuerpos para integrina vla-1.
|
|
ES2312586T3
(es)
|
2001-06-22 |
2009-03-01 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibidor del crecimiento celular que contenga un anticuerpo anti-clipicano 3.
|
|
CA2447851C
(en)
*
|
2001-06-28 |
2012-08-28 |
Domantis Limited |
Dual-specific ligand and its use
|
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
|
PL374495A1
(en)
*
|
2001-10-15 |
2005-10-31 |
Immunomedics, Inc. |
Direct targeting binding proteins
|
|
US20030157108A1
(en)
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
|
DE10156482A1
(de)
|
2001-11-12 |
2003-05-28 |
Gundram Jung |
Bispezifisches Antikörper-Molekül
|
|
WO2003068801A2
(en)
*
|
2002-02-11 |
2003-08-21 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040110226A1
(en)
|
2002-03-01 |
2004-06-10 |
Xencor |
Antibody optimization
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
JP4386741B2
(ja)
|
2002-04-15 |
2009-12-16 |
中外製薬株式会社 |
ｓｃＤｂライブラリーの作成方法
|
|
ATE428778T1
(de)
|
2002-04-26 |
2009-05-15 |
Chugai Pharmaceutical Co Ltd |
Verfahren zum screening auf agonistische antikörper
|
|
WO2005056606A2
(en)
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Optimized antibodies that target the epidermal growth factor receptor
|
|
JP2004086862A
(ja)
|
2002-05-31 |
2004-03-18 |
Celestar Lexico-Sciences Inc |
タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
|
|
US20050130224A1
(en)
*
|
2002-05-31 |
2005-06-16 |
Celestar Lexico- Sciences, Inc. |
Interaction predicting device
|
|
WO2003104425A2
(en)
|
2002-06-07 |
2003-12-18 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Novel stable anti-cd22 antibodies
|
|
EP1511861A4
(en)
|
2002-06-12 |
2007-12-05 |
Genencor Int |
METHODS AND BINDING COMPOSITIONS DEPENDENT FROM THE MEDIUM OF A TARGET AGENT TO A TARGET
|
|
EP1517921B1
(en)
|
2002-06-28 |
2006-06-07 |
Domantis Limited |
Dual specific ligands with increased serum half-life
|
|
PT2314629E
(pt)
|
2002-07-18 |
2014-01-22 |
Merus B V |
Produção recombinante de misturas de anticorpos
|
|
CA2492524A1
(en)
|
2002-08-15 |
2004-02-26 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
|
AU2003257536A1
(en)
*
|
2002-08-27 |
2004-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method of stabilizing protein solution preparation
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
AU2003271175A1
(en)
|
2002-10-11 |
2004-05-04 |
Masahiro Abe |
Cell death-inducing agent
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
GB0224082D0
(en)
*
|
2002-10-16 |
2002-11-27 |
Celltech R&D Ltd |
Biological products
|
|
PL216630B1
(pl)
|
2002-10-17 |
2014-04-30 |
Genmab As |
Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
|
|
CN102746399B
(zh)
|
2002-12-24 |
2016-03-02 |
里纳特神经系统学公司 |
抗ngf抗体及其使用方法
|
|
WO2004060919A1
(ja)
|
2002-12-26 |
2004-07-22 |
Chugai Seiyaku Kabushiki Kaisha |
ヘテロ受容体に対するアゴニスト抗体
|
|
JP4477579B2
(ja)
|
2003-01-21 |
2010-06-09 |
中外製薬株式会社 |
抗体の軽鎖スクリーニング方法
|
|
US7223393B2
(en)
|
2003-02-07 |
2007-05-29 |
Pdl Biopharma, Inc |
Amphiregulin antibodies and their use to treat cancer and psoriasis
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
EP1616880A4
(en)
|
2003-03-13 |
2006-07-26 |
Chugai Pharmaceutical Co Ltd |
LIGAND WITH AGONISTIC ACTIVITY AGAINST A MUTED RECEPTOR
|
|
JP2004279086A
(ja)
*
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
|
WO2004087763A1
(ja)
|
2003-03-31 |
2004-10-14 |
Chugai Seiyaku Kabushiki Kaisha |
Ｃｄ２２に対する改変抗体およびその利用
|
|
GB2400851B
(en)
|
2003-04-25 |
2004-12-15 |
Bioinvent Int Ab |
Identifying binding of a polypeptide to a polypeptide target
|
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
|
EP2395016A3
(en)
*
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
|
AU2004256042A1
(en)
|
2003-06-05 |
2005-01-20 |
Genentech, Inc. |
BlyS antagonists and uses thereof
|
|
US8597911B2
(en)
*
|
2003-06-11 |
2013-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing antibodies
|
|
EP1636264A2
(en)
|
2003-06-24 |
2006-03-22 |
MERCK PATENT GmbH |
Tumour necrosis factor receptor molecules with reduced immunogenicity
|
|
WO2005005604A2
(en)
|
2003-06-30 |
2005-01-20 |
Centocor, Inc. |
Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
|
|
US7297336B2
(en)
|
2003-09-12 |
2007-11-20 |
Baxter International Inc. |
Factor IXa specific antibodies displaying factor VIIIa like activity
|
|
JP2005101105A
(ja)
|
2003-09-22 |
2005-04-14 |
Canon Inc |
位置決め装置、露光装置、デバイス製造方法
|
|
JP2005112514A
(ja)
|
2003-10-06 |
2005-04-28 |
Tadano Ltd |
伸縮ブーム
|
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
|
KR101333449B1
(ko)
*
|
2003-12-10 |
2013-11-26 |
메다렉스, 엘.엘.시. |
Ｉｐ―１０ 항체 및 그의 용도
|
|
KR101151477B1
(ko)
|
2003-12-10 |
2012-06-22 |
메다렉스, 인코포레이티드 |
인터페론 알파 항체 및 그의 용도
|
|
TW200530266A
(en)
*
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Method of reinforcing antibody activity
|
|
JPWO2005056602A1
(ja)
*
|
2003-12-12 |
2008-03-06 |
中外製薬株式会社 |
アゴニスト活性を有する改変抗体のスクリーニング方法
|
|
TW200530269A
(en)
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Anti-Mpl antibodies
|
|
WO2005056605A1
(ja)
*
|
2003-12-12 |
2005-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
３量体以上の受容体を認識する改変抗体
|
|
AR048210A1
(es)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
Un agente preventivo para la vasculitis.
|
|
CA2550996A1
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
|
ES2397631T3
(es)
|
2003-12-25 |
2013-03-08 |
Kyowa Hakko Kirin Co., Ltd. |
Mutante antagonista de anticuerpos ANTI-CD40
|
|
US20050266425A1
(en)
*
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
|
SI2177537T1
(sl)
|
2004-01-09 |
2012-01-31 |
Pfizer |
Protitielesa proti MAdCAM
|
|
CN1330448C
(zh)
*
|
2004-02-25 |
2007-08-08 |
苏州宝时得电动工具有限公司 |
往复式电动工具的往复杆平衡机构
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
AR048335A1
(es)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
|
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
|
TW200605906A
(en)
|
2004-05-11 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Remedy for thrombopenia
|
|
CA2569509C
(en)
|
2004-06-03 |
2014-08-12 |
Novimmune S.A. |
Anti-cd3 antibodies and methods of use thereof
|
|
KR100620554B1
(ko)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
Ｔａｇ-72에 대한 인간화 항체
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
CA2572133A1
(en)
*
|
2004-06-25 |
2006-01-12 |
Medimmune, Inc. |
Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
|
|
DE102004032634A1
(de)
|
2004-07-06 |
2006-02-16 |
Sms Demag Ag |
Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
|
|
PL1674111T3
(pl)
|
2004-07-09 |
2011-04-29 |
Chugai Pharmaceutical Co Ltd |
Przeciwciała anty-glipikan 3
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
ES2426817T3
(es)
|
2004-08-04 |
2013-10-25 |
Mentrik Biotech, Llc |
Regiones Fc variantes
|
|
AU2005282700A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
US7572456B2
(en)
|
2004-09-13 |
2009-08-11 |
Macrogenics, Inc. |
Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
|
|
WO2006031994A2
(en)
|
2004-09-14 |
2006-03-23 |
Xencor, Inc. |
Monomeric immunoglobulin fc domains
|
|
EP1799718A1
(en)
|
2004-09-14 |
2007-06-27 |
National Institute for Biological Standards and Control (NIBSC) |
Vaccine
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
WO2006033386A1
(ja)
|
2004-09-22 |
2006-03-30 |
Kirin Beer Kabushiki Kaisha |
安定化されたヒトIgG4抗体
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
NZ554520A
(en)
|
2004-10-22 |
2010-03-26 |
Amgen Inc |
Methods for refolding of recombinant antibodies
|
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
|
US7632497B2
(en)
*
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
|
AU2005317279C1
(en)
|
2004-12-14 |
2014-07-17 |
Cytiva Bioprocess R&D Ab |
Purification of immunoglobulins
|
|
EP2208783A1
(en)
|
2004-12-22 |
2010-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
|
|
US8728828B2
(en)
|
2004-12-22 |
2014-05-20 |
Ge Healthcare Bio-Sciences Ab |
Purification of immunoglobulins
|
|
US20090087478A1
(en)
|
2004-12-27 |
2009-04-02 |
Progenics Pharmaceuticals (Nevada), Inc. |
Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
|
|
MX2007007935A
(es)
|
2004-12-28 |
2007-12-06 |
Innate Pharma Sa |
Anticuerpos monoclonales contra nkg2a.
|
|
US20060275282A1
(en)
*
|
2005-01-12 |
2006-12-07 |
Xencor, Inc. |
Antibodies and Fc fusion proteins with altered immunogenicity
|
|
JP4986633B2
(ja)
|
2005-01-12 |
2012-07-25 |
協和発酵キリン株式会社 |
安定化されたヒトＩｇＧ２およびＩｇＧ３抗体
|
|
US20060263357A1
(en)
|
2005-05-05 |
2006-11-23 |
Tedder Thomas F |
Anti-CD19 antibody therapy for autoimmune disease
|
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
|
EP1870458B1
(en)
|
2005-03-31 |
2018-05-09 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 STRUCTURAL ISOMERS
|
|
EP1871808A2
(en)
|
2005-03-31 |
2008-01-02 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
|
EP2824183B1
(en)
|
2005-04-08 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing bispecific antibodies
|
|
CA2605037C
(en)
|
2005-04-15 |
2015-02-24 |
Genentech, Inc. |
Hgf beta chain variants
|
|
WO2006116260A2
(en)
|
2005-04-26 |
2006-11-02 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
|
US20090028854A1
(en)
*
|
2005-06-10 |
2009-01-29 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 SITE-DIRECTED MUTANT
|
|
CN101262885B
(zh)
*
|
2005-06-10 |
2015-04-01 |
中外制药株式会社 |
含有sc(Fv)2的药物组合物
|
|
CA2610987C
(en)
*
|
2005-06-10 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
|
AU2006261920A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
|
CN101627054A
(zh)
|
2005-07-11 |
2010-01-13 |
马克罗基因公司 |
用人源化抗cd16a抗体治疗自身免疫疾病的方法
|
|
CA2618681C
(en)
|
2005-08-10 |
2015-10-27 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
EP1915397B1
(en)
|
2005-08-19 |
2015-01-14 |
Wyeth LLC |
Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
|
|
AU2006297173A1
(en)
|
2005-09-29 |
2007-04-12 |
Viral Logic Systems Technology Corp. |
Immunomodulatory compositions and uses therefor
|
|
RU2446826C2
(ru)
|
2005-10-14 |
2012-04-10 |
Фукуока Юниверсити |
Агенты для подавления повреждения трансплантированных островков после трансплантации островков
|
|
JP5191235B2
(ja)
|
2005-10-21 |
2013-05-08 |
中外製薬株式会社 |
心疾患治療剤
|
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
|
AU2007227963A1
(en)
|
2006-03-23 |
2007-09-27 |
Kyowa Hakko Kirin Co., Ltd. |
Agonist antibody to human thrombopoietin receptor
|
|
ES2395969T3
(es)
|
2006-03-24 |
2013-02-18 |
Merck Patent Gmbh |
Dominios de proteínas heterodiméricas genéticamente modificados
|
|
WO2007114325A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
|
IN2014DN10515A
(enExample)
*
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
|
CA2648644C
(en)
|
2006-04-07 |
2016-01-05 |
Osaka University |
Muscle regeneration promoter
|
|
WO2007145941A2
(en)
|
2006-06-06 |
2007-12-21 |
Tolerrx, Inc. |
Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
|
|
CL2007001665A1
(es)
*
|
2006-06-08 |
2008-01-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
|
|
EP2035456A1
(en)
|
2006-06-22 |
2009-03-18 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
|
EP2107115A1
(en)
|
2007-01-24 |
2009-10-07 |
Kyowa Hakko Kirin Co., Ltd. |
Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
EP2139924B1
(en)
|
2007-03-29 |
2016-07-06 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
EP2666787B1
(en)
|
2007-05-31 |
2022-02-09 |
Genmab A/S |
STABLE IgG4 ANTIBODIES
|
|
US20100291023A1
(en)
|
2007-05-31 |
2010-11-18 |
Genmab A/S |
Method for extending the half-life of exogenous or endogenous soluble molecules
|
|
AU2008270710A1
(en)
|
2007-06-29 |
2009-01-08 |
Merck Sharp & Dohme Corp. |
MDL-1 uses
|
|
EP2031064A1
(de)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
|
MX2010002683A
(es)
|
2007-09-14 |
2010-03-26 |
Amgen Inc |
Poblaciones de anticuerpos homogeneos.
|
|
MX336725B
(es)
|
2007-09-26 |
2016-01-28 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
|
WO2009041621A1
(ja)
|
2007-09-26 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
抗il-6レセプター抗体
|
|
WO2009041734A1
(ja)
|
2007-09-26 |
2009-04-02 |
Kyowa Hakko Kirin Co., Ltd. |
ヒトトロンボポエチン受容体に対するアゴニスト抗体
|
|
DK3059246T3
(en)
*
|
2007-09-26 |
2018-10-01 |
Chugai Pharmaceutical Co Ltd |
Modified constant region of an antibody
|
|
AR066172A1
(es)
|
2007-09-28 |
2009-07-29 |
Chugai Pharmaceutical Co Ltd |
Metodo para la preparacion de un anticuerpo antiglipicano 3 con modulada cinetica plasmatica mediante variacion de la semivida plasmatica.
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
JP5314033B2
(ja)
|
2007-10-22 |
2013-10-16 |
メルク セローノ ソシエテ アノニム |
突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
|
|
BRPI0821110B8
(pt)
|
2007-12-05 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
|
|
CN105732813A
(zh)
|
2007-12-18 |
2016-07-06 |
生物联合公司 |
识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
SI2235064T1
(sl)
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
|
EP2250279B1
(en)
|
2008-02-08 |
2016-04-13 |
MedImmune, LLC |
Anti-ifnar1 antibodies with reduced fc ligand affinity
|
|
SI2274008T1
(sl)
|
2008-03-27 |
2014-08-29 |
Zymogenetics, Inc. |
Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
|
|
TWI700293B
(zh)
|
2008-04-11 |
2020-08-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗體
|
|
JP5646457B2
(ja)
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
US9315577B2
(en)
|
2008-05-01 |
2016-04-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
BRPI0919382A2
(pt)
|
2008-09-26 |
2016-01-05 |
Roche Glycart Ag |
anticorpos bi-específicos anti-egfr/anti-igf-1r
|
|
WO2010064090A1
(en)
|
2008-12-02 |
2010-06-10 |
Pierre Fabre Medicament |
Process for the modulation of the antagonistic activity of a monoclonal antibody
|
|
AR074438A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
|
|
DE202008016028U1
(de)
|
2008-12-04 |
2010-04-15 |
Melitta Haushaltsprodukte Gmbh & Co. Kg |
Behälter zur Aufbewahrung von Gegenständen
|
|
WO2010085682A2
(en)
|
2009-01-23 |
2010-07-29 |
Biogen Idec Ma Inc. |
Stabilized fc polypeptides with reduced effector function and methods of use
|
|
SG173705A1
(en)
|
2009-03-05 |
2011-09-29 |
Abbott Lab |
Il-17 binding proteins
|
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
JP5787446B2
(ja)
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
|
KR20120057565A
(ko)
|
2009-04-01 |
2012-06-05 |
제넨테크, 인크. |
항-ＦｃＲＨ５ 항체 및 면역접합체 및 사용 방법
|
|
CN102369214B
(zh)
|
2009-04-07 |
2019-04-12 |
罗氏格黎卡特股份公司 |
三价、双特异性抗体
|
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
|
KR101747103B1
(ko)
|
2009-06-26 |
2017-06-14 |
리제너론 파마슈티칼스 인코포레이티드 |
천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
|
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
RU2606264C2
(ru)
|
2009-12-25 |
2017-01-10 |
Чугаи Сеияку Кабушики Каиша |
Способ полипептидной модификации для очистки полипептидных мультимеров
|
|
SG181952A1
(en)
|
2009-12-29 |
2012-07-30 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
中外製藥股份有限公司 |
Stabilized antibody solution containing
|
|
WO2011091181A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
|
US9023997B2
(en)
|
2010-01-20 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Anti-ILT5 antibodies and ILT5-binding antibody fragments
|
|
CA2791652C
(en)
|
2010-03-02 |
2018-06-12 |
Kyowa Kirin Co., Ltd. |
Modified antibody composition
|
|
EP2543730B1
(en)
*
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
EP2545079A2
(en)
|
2010-03-11 |
2013-01-16 |
Rinat Neuroscience Corporation |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
|
KR20130018256A
(ko)
|
2010-03-31 |
2013-02-20 |
제이에스알 가부시끼가이샤 |
친화성 크로마토그래피용 충전제
|
|
PL2560993T3
(pl)
|
2010-04-20 |
2024-11-04 |
Genmab A/S |
Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
|
|
US9637557B2
(en)
|
2010-04-23 |
2017-05-02 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
CA2797981C
(en)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
WO2012020096A1
(en)
|
2010-08-13 |
2012-02-16 |
Medimmune Limited |
Monomeric polypeptides comprising variant fc regions and methods of use
|
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
JP6013915B2
(ja)
|
2010-11-17 |
2016-10-25 |
中外製薬株式会社 |
血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
WO2012145238A2
(en)
|
2011-04-20 |
2012-10-26 |
Tolerx, Inc. |
Methods for reducing an adverse immune response to a foreign antigen in a human subject with anti-cd4 antibodies or cd4-binding fragments thereof or cd4-binding molecules
|
|
HUE044633T2
(hu)
|
2011-10-27 |
2019-11-28 |
Genmab As |
Heterodimer fehérjék elõállítása
|
|
EP2787078B1
(en)
|
2011-10-31 |
2019-05-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
|
AU2012332021B8
(en)
|
2011-11-04 |
2017-10-12 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
WO2014067011A1
(en)
|
2012-11-02 |
2014-05-08 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
MX351148B
(es)
|
2012-03-08 |
2017-10-04 |
Hoffmann La Roche |
Formulacion de anticuerpo beta amiloide.
|
|
EP2825559B1
(en)
|
2012-03-13 |
2019-02-27 |
Novimmune SA |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
EP2832856A4
(en)
|
2012-03-29 |
2016-01-27 |
Chugai Pharmaceutical Co Ltd |
ANTI-LAMP5 ANTIBODIES AND USE THEREOF
|
|
DK2838917T3
(da)
|
2012-04-20 |
2019-08-26 |
Merus Nv |
Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
|
|
TWI596115B
(zh)
|
2012-08-13 |
2017-08-21 |
再生元醫藥公司 |
具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
|
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
|
CA2904528C
(en)
|
2013-03-15 |
2021-01-19 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
|
SG10201803449VA
(en)
|
2013-09-27 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
|
EP3066133A1
(en)
|
2013-11-04 |
2016-09-14 |
Glenmark Pharmaceuticals S.A. |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
|
TWI831106B
(zh)
|
2014-06-20 |
2024-02-01 |
日商中外製藥股份有限公司 |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
|
JP6630036B2
(ja)
|
2014-09-30 |
2020-01-15 |
Jsr株式会社 |
標的物の精製方法、及び、ミックスモード用担体
|
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
JP6698102B2
(ja)
|
2015-04-17 |
2020-05-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
凝固因子と多重特異的抗体を用いた併用療法
|
|
JP2018123055A
(ja)
|
2015-04-24 |
2018-08-09 |
公立大学法人奈良県立医科大学 |
血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
|
|
CA3004288C
(en)
|
2015-12-28 |
2025-05-27 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
|
|
AU2017255077B2
(en)
|
2016-04-28 |
2024-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing preparation
|
|
US20210107994A1
(en)
|
2017-03-31 |
2021-04-15 |
Public University Corporation Nara Medical University |
Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
|